WILMINGTON, Del., June 02, 2025--Positive results from the DESTINY-Breast09 Phase III trial showed ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab demonstrated a highly statistically ...

Trastuzumab deruxtecan plus pertuzumab significantly extends PFS compared to THP in HER2-positive metastatic breast cancer. The combination demonstrated a 44% lower risk of disease progression or ...

Focus. Human epidermal growth factor receptor 2 (HER2)-positive locally advanced or metastatic breast cancer. Population. 1,157 total patients, 770 of whom were randomized to receive either ...

Topline results were announced from a phase 3 trial evaluating fam-trastuzumab deruxtecan-nxki in combination with pertuzumab as a first-line treatment for patients with human epidermal growth ...

The EMA approved pertuzumab for combination use with trastuzumab and docetaxel for adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer in 2013. 5 Pertuzumab is ...

Subcutaneous pertuzumab (Perjeta) and trastuzumab (Herceptin) plus chemotherapy given in the neoadjuvant setting for patients with HER2-positive early breast cancer demonstrated similar efficacy and ...

Figure 2 The complementary mechanisms of pertuzumab and trastuzumab. (Left) HER2 receptors on the surface of the HER2-expressing breast cancer cells can dimerize with themselves or with other HER ...

Experimental anti-HER2 agents including novel anti-HER2 antibodies (margetuximab 25 and trastuzumab deruxtecan), 26 tyrosine-kinase inhibitors (neratinib, 27 tucatinib 28 and pyrotinib), 29 CDK 4/6 ...

Data from 83 patients who received anti-HER2 therapy in the neoadjuvant setting at Jewish General Hospital between 2015 and 2021showed that adding pertuzumab to trastuzumab resulted in a pCR rate at ...